216 related articles for article (PubMed ID: 18459173)
1. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.
Lipton A; Cook R; Saad F; Major P; Garnero P; Terpos E; Brown JE; Coleman RE
Cancer; 2008 Jul; 113(1):193-201. PubMed ID: 18459173
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
Lipton A; Cook RJ; Major P; Smith MR; Coleman RE
Oncologist; 2007 Sep; 12(9):1035-43. PubMed ID: 17914073
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.
Hirsh V; Major PP; Lipton A; Cook RJ; Langer CJ; Smith MR; Brown JE; Coleman RE
J Thorac Oncol; 2008 Mar; 3(3):228-36. PubMed ID: 18317064
[TBL] [Abstract][Full Text] [Related]
4. Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.
Lipton A; Cook R; Brown J; Body JJ; Smith M; Coleman R
Clin Oncol (R Coll Radiol); 2013 Apr; 25(4):217-26. PubMed ID: 23219232
[TBL] [Abstract][Full Text] [Related]
5. N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases.
Ferreira AR; Alho I; Shan N; Matias M; Faria M; Casimiro S; Leitzel K; Ali S; Lipton A; Costa L
Oncologist; 2016 Dec; 21(12):1418-1426. PubMed ID: 27534575
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].
Hu XY; Zou QF; Jin C; Li WD; Chen WS; Ma L
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun; 30(6):1343-6. PubMed ID: 20584674
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.
Coleman RE; Major P; Lipton A; Brown JE; Lee KA; Smith M; Saad F; Zheng M; Hei YJ; Seaman J; Cook R
J Clin Oncol; 2005 Aug; 23(22):4925-35. PubMed ID: 15983391
[TBL] [Abstract][Full Text] [Related]
8. Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer.
Rajpar S; Massard C; Laplanche A; Tournay E; Gross-Goupil M; Loriot Y; Di Palma M; Bossi A; Escudier B; Chauchereau A; Fizazi K
Ann Oncol; 2010 Sep; 21(9):1864-1869. PubMed ID: 20181574
[TBL] [Abstract][Full Text] [Related]
9. [Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma].
Dong M; Feng FY; Zhang Y; Xie GR; Wang YJ; Liu JW; Song ST; Zhou QH; Ren J; Jiao SC; Li J; Wang XW; Chen Q; Wang ZH; Xu N; Feng JF
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):215-20. PubMed ID: 18756940
[TBL] [Abstract][Full Text] [Related]
10. N-telopeptide of type I collagen is useful for monitoring therapeutic response in non-small cell lung cancer patients with bone metastases.
Kaira R; Murakami H; Kaira K; Takahashi T; Tsuya A; Nakamura Y; Naito T; Endo M; Yamamoto N
Int J Clin Oncol; 2010 Oct; 15(5):484-8. PubMed ID: 20556457
[TBL] [Abstract][Full Text] [Related]
11. Utility of urinary type I collagen cross-linked N-telopeptide as a prognostic indicator in breast cancer patients with bone metastases.
Shizuku M; Shibata M; Okumura M; Takeuchi D; Kikumori T; Mizuno Y
Breast Cancer; 2020 Nov; 27(6):1065-1071. PubMed ID: 32415556
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid.
Zhao X; Xu X; Zhang Q; Jia Z; Sun S; Zhang J; Wang B; Wang Z; Hu X
BMC Cancer; 2011 Sep; 11():403. PubMed ID: 21936956
[TBL] [Abstract][Full Text] [Related]
13. Urinary N telopeptide levels in predicting the anti-nociceptive responses of zoledronic acid and paclitaxel in a rat model of bone metastases.
Gui Q; Xu C; Li D; Zhuang L; Xia S; Yu S
Mol Med Rep; 2015 Sep; 12(3):4243-4249. PubMed ID: 26081451
[TBL] [Abstract][Full Text] [Related]
14. Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases.
Zhao YY; Xue C; Hou X; Liao H; Li S; Zhao HY; Huang Y; Chen LK; Xu F; Liu JL; Zhang L
Eur J Cancer; 2011 Apr; 47(6):848-53. PubMed ID: 21256000
[TBL] [Abstract][Full Text] [Related]
15. Markers of bone resorption in patients treated with pamidronate.
Lipton A; Demers L; Curley E; Chinchilli V; Gaydos L; Hortobagyi G; Theriault R; Clemens D; Costa L; Seaman J; Knight R
Eur J Cancer; 1998 Dec; 34(13):2021-6. PubMed ID: 10070304
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
17. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
Pectasides D; Nikolaou M; Farmakis D; Kanakis I; Gaglia A; Kountourakis P; Karamanos NK; Economopoulos T; Raptis SA
Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
Berenson JR; Rosen LS; Howell A; Porter L; Coleman RE; Morley W; Dreicer R; Kuross SA; Lipton A; Seaman JJ
Cancer; 2001 Apr; 91(7):1191-200. PubMed ID: 11283917
[TBL] [Abstract][Full Text] [Related]
20. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Chen B;
J Natl Cancer Inst; 2002 Oct; 94(19):1458-68. PubMed ID: 12359855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
